Keywords: مهارکننده TNF; biologic; cardiovascular; mortality; myocardial infarction; psoriasis; stroke; TNF inhibitor;
مقالات ISI مهارکننده TNF (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهارکننده TNF; TNF Inhibitor; IBD Treatment; Patient Management; Inflammation; ADA; adalimumab; CD; Crohn's disease; IBD; inflammatory bowel disease; IFX; infliximab; IM; immunomodulator; IQR; interquartile range; TNF; tumor necrosis factor; UC; ulcerative colitis;
Keywords: مهارکننده TNF; Switching; TNF inhibitor; Axial spondyloarthritis; Review;
Keywords: مهارکننده TNF; Biologic agents; adverse effect; infection; autoimmunity; paradoxical inflammation; ANA; Antinuclear antibody; AS; Ankylosing spondylitis; DMARD; Disease-modifying antirheumatic drug; IBD; Inflammatory bowel disease; ILD; Interstitial lung disease; NTM; N
Keywords: مهارکننده TNF; TNF inhibitor; Immunogenicity; Antidrug antibody; Rheumatoid arthritis; Ankylosing spondylitis;
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease
Keywords: مهارکننده TNF; TNF inhibitor; immune-mediated inflammatory diseases; children; AE; Adverse event; CD; Crohn's disease; CHF; Congestive heart failure; ERA; Enthesitis-related arthritis; JIA; Juvenile idiopathic arthritis; NCT; National Clinical Trial; pJIA; Polyarticular
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis
Keywords: مهارکننده TNF; Polymyositis; Dermatomyositis; Infliximab; TNF inhibitor;
Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment
Keywords: مهارکننده TNF; Rheumatoid arthritis; Tuberculosis; TNF inhibitor; Biologic DMARDs;
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Keywords: مهارکننده TNF; CDAI; MUSIC Trial; PK Study; TNF Inhibitor; BMI; body mass index; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CDEIS; Crohn's Disease Endoscopic Index of Severity; CI; confidence interval; CRP; C-reactive protein; CZP; certolizumab pegol; MU
Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis
Keywords: مهارکننده TNF; ankylosing spondylitis; endothelium; ADMA; SDMA; TNF inhibitor
Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure
Keywords: مهارکننده TNF; Rheumatoid arthritis; Rituximab; TNF inhibitor; Retreatment
SPECIAL ARTICLERecommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus
Keywords: مهارکننده TNF; Ulcerative colitis; Treatment; Consensus; Colectomy; TNF inhibitor; Biologic; Infliximab;
Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature
Keywords: مهارکننده TNF; Crohn's disease; Hodgkin lymphoma; Immunosuppression; Lymphoproliferative disorder; Reed-Sternberg cells; TNF inhibitor
Anti-TNF therapy: Safety aspects of taking the risk
Keywords: مهارکننده TNF; TNF inhibitor; Adalimumab; Etanercept; Infliximab; Rheumatoid arthritis; DMARDs; Infection; Malignancy; Drug survival; Biological therapy; Infections; Malignancies; Cancer; Anti-TNF therapy